Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProImmune has launched a new in vitro cytokine release assay, ProStorm, designed for assessing the likelihood of first infusion reactions to novel therapeutics.
Subscribe to our email newsletter
By using fresh undiluted whole blood from a large cohort of donors, the ProStorm assay provides a sensitive evaluation of cytokine responses to a therapeutic in one simple step.
The company claimed that ProStorm is designed specifically to indicate when a cytokine storm first infusion reaction may be a risk for a drug.
ProImmune CEO Nikolai Schwabe said first infusion cytokine storm reactions to new therapeutics can represent a substantial stumbling block to drug development.
"Now, using the ProStorm assay service, developers of biologics can gain valuable information to inform the design of their first-in-man trials," Schwabe added.
"By offering ProStorm, we at ProImmune are extending the range of services we offer to help our clients bring safe and effective therapeutics to market."